Published in Proc Natl Acad Sci U S A on August 13, 2012
Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun (2015) 1.79
STAT3, a Poor Survival Predicator, Is Associated with Lymph Node Metastasis from Breast Cancer. J Breast Cancer (2013) 1.00
How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT (2013) 0.93
STAT3 in Cancer-Friend or Foe? Cancers (Basel) (2014) 0.93
Tumor-derived mutations in the gene associated with retinoid interferon-induced mortality (GRIM-19) disrupt its anti-signal transducer and activator of transcription 3 (STAT3) activity and promote oncogenesis. J Biol Chem (2013) 0.92
Combined targeting of STAT3/NF-κB/COX-2/EP4 for effective management of pancreatic cancer. Clin Cancer Res (2014) 0.90
Differential roles of STAT3 in the initiation and growth of lung cancer. Oncogene (2014) 0.89
Cancer Stem Cell Hierarchy in Glioblastoma Multiforme. Front Surg (2016) 0.87
STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance. Front Oncol (2015) 0.86
Role of stat3 in skin carcinogenesis: insights gained from relevant mouse models. J Skin Cancer (2013) 0.86
PARD3 Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. Cancer Res (2015) 0.84
Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinoma. BMC Vet Res (2015) 0.84
Recombinant leukemia inhibitory factor suppresses human medullary thyroid carcinoma cell line xenografts in mice. Cancer Lett (2013) 0.83
A firmer understanding of the effect of hypergravity on thyroid tissue: cholesterol and thyrotropin receptor. PLoS One (2014) 0.82
Human papillomavirus infection correlates with inflammatory Stat3 signaling activity and IL-17 level in patients with colorectal cancer. PLoS One (2015) 0.82
STAT3 Activities and Energy Metabolism: Dangerous Liaisons. Cancers (Basel) (2014) 0.81
STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b. Cancers (Basel) (2014) 0.81
Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal. Front Oncol (2016) 0.80
The Role of STAT3 in Thyroid Cancer. Cancers (Basel) (2014) 0.80
Sprouty1 induces a senescence-associated secretory phenotype by regulating NFκB activity: implications for tumorigenesis. Cell Death Differ (2013) 0.79
Aberrant activation of signal transducer and activator of transcription-3 (STAT3) signaling in endometriosis. Hum Reprod (2015) 0.79
CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity. Sci Rep (2016) 0.79
Obesity and thyroid cancer: is leptin the (only) link? Endocrinology (2013) 0.78
A single nucleotide polymorphism in the 3'-UTR of STAT3 regulates its expression and reduces risk of pancreatic cancer in a Chinese population. Oncotarget (2016) 0.78
Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice. Leukemia (2015) 0.78
mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency. Oncotarget (2016) 0.78
Role of STAT3 in lung cancer. JAKSTAT (2015) 0.77
STAT3β controls inflammatory responses and early tumor onset in skin and colon experimental cancer models. Am J Cancer Res (2014) 0.77
Aberrant sonic hedgehog signaling pathway and STAT3 activation in papillary thyroid cancer. Int J Clin Exp Med (2014) 0.76
Human papillomavirus infection correlates with inflammatory Stat3 signaling activity and IL-17 expression in patients with breast cancer. Am J Transl Res (2016) 0.76
The leukemia inhibitory factor (LIF) and p21 mediate the TGFβ tumor suppressive effects in human cutaneous melanoma. BMC Cancer (2015) 0.75
Expression of signal transducer and activator of transcription 3 and its phosphorylated form is significantly upregulated in patients with papillary thyroid cancer. Exp Ther Med (2015) 0.75
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications. J Clin Med Res (2016) 0.75
Arctigenin inhibits STAT3 and exhibits anticancer potential in human triple-negative breast cancer therapy. Oncotarget (2016) 0.75
Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E). Cancer Lett (2015) 0.75
Cancer cell metabolism: Warburg and beyond. Cell (2008) 11.80
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer (2008) 11.50
Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc (2006) 8.42
Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol (1989) 7.47
Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell (2011) 7.33
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell (2008) 6.84
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Interleukin-6: from basic science to medicine--40 years in immunology. Annu Rev Immunol (2005) 5.27
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Function of mitochondrial Stat3 in cellular respiration. Science (2009) 5.13
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell (2009) 4.47
Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol (1998) 4.09
Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol Cell (2012) 3.98
Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science (2009) 3.89
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med (2006) 3.47
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res (2002) 3.25
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res (2005) 3.10
Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene (2005) 3.05
Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther (2006) 2.93
Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev (2008) 2.61
Cobalt inhibits the interaction between hypoxia-inducible factor-alpha and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. J Biol Chem (2003) 2.36
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem (2006) 2.15
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer (2008) 2.11
Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One (2009) 1.90
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A (2011) 1.82
Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res (2008) 1.78
Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol (2008) 1.76
Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res (2003) 1.75
Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A (2005) 1.70
A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction. Aging (Albany NY) (2010) 1.70
Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology (2009) 1.64
p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology (2011) 1.60
The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol (2003) 1.44
Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells. Mol Cancer Res (2008) 1.43
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines. Thyroid (2007) 1.41
IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype. Carcinogenesis (2009) 1.34
Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.31
Stat3 is required for the development of skin cancer. J Clin Invest (2004) 1.26
A SOCS-1 peptide mimetic inhibits both constitutive and IL-6 induced activation of STAT3 in prostate cancer cells. Oncogene (2005) 1.24
STAT3 can serve as a hit in the process of malignant transformation of primary cells. Cell Death Differ (2012) 1.24
Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3. Mitochondrion (2011) 1.17
Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformation. Breast Cancer Res (2010) 1.17
Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines. Mol Cancer Ther (2009) 1.10
mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab (2012) 1.08
Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation. Mol Endocrinol (2003) 1.06
Environment, inflammation, and cancer. Curr Opin Genet Dev (2010) 1.06
In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs (2006) 1.06
STAT3 inhibits the degradation of HIF-1alpha by pVHL-mediated ubiquitination. Exp Mol Med (2008) 1.06
IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene (2010) 1.05
RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response. Endocr Relat Cancer (2005) 1.04
MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene (2001) 1.03
Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis. Clin Cancer Res (2010) 1.02
Reactivation of IGFBP7 by DNA demethylation inhibits human colon cancer cell growth in vitro. Cancer Biol Ther (2008) 0.97
IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. J Biol Chem (2004) 0.96
From the nucleus to the mitochondria and back: the odyssey of a multitask STAT3. Cell Cycle (2011) 0.93
Molecular genetics of papillary thyroid carcinoma: great expectations. Arq Bras Endocrinol Metabol (2007) 0.92
RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor. Cancer Res (2005) 0.92
Basal STAT3 activities are negatively correlated with tumor size in papillary thyroid carcinomas. J Endocrinol Invest (2011) 0.87
Upregulation of the signal transducers and activators of transcription 3 (STAT3) pathway in lymphatic metastases of papillary thyroid cancer. Int J Clin Exp Pathol (2011) 0.86
Desmoplastic stromal reaction in papillary thyroid microcarcinoma. Histopathology (2011) 0.85
Hypoxia-induced SOCS3 is limiting STAT3 phosphorylation and NF-κB activation in congenital heart disease. Biochimie (2011) 0.79
Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance. Endocr Relat Cancer (2008) 0.79
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med (2012) 11.14
Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell (2002) 9.36
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science (2003) 7.86
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol (2011) 7.65
Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med (2003) 7.14
CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest (2008) 5.96
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
The metastatic niche: adapting the foreign soil. Nat Rev Cancer (2009) 5.28
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med (2006) 5.22
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer (2002) 5.02
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. Nature (2010) 4.78
Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med (2003) 4.69
Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst (2002) 4.43
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med (2002) 4.00
Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res (2009) 3.56
The banana (Musa acuminata) genome and the evolution of monocotyledonous plants. Nature (2012) 3.53
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
The perivascular niche regulates breast tumour dormancy. Nat Cell Biol (2013) 3.36
BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene (2003) 3.34
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab (2009) 3.23
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med (2013) 3.21
Frequency of TERT promoter mutations in human cancers. Nat Commun (2013) 3.13
Migratory neighbors and distant invaders: tumor-associated niche cells. Genes Dev (2008) 2.95
Preparing the "soil": the premetastatic niche. Cancer Res (2006) 2.92
The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol (2011) 2.83
AC133/CD133/Prominin-1. Int J Biochem Cell Biol (2005) 2.80
Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest (2005) 2.77
Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas. Cancer Discov (2013) 2.65
Role of sulphuric acid, ammonia and galactic cosmic rays in atmospheric aerosol nucleation. Nature (2011) 2.65
Expansion and maintenance of human embryonic stem cell-derived endothelial cells by TGFbeta inhibition is Id1 dependent. Nat Biotechnol (2010) 2.54
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology (2003) 2.39
The mTOR signalling pathway in human cancer. Int J Mol Sci (2012) 2.38
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res (2007) 2.32
Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res (2006) 2.31
Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma. Thyroid (2014) 2.31
Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc Natl Acad Sci U S A (2004) 2.25
Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res (2005) 2.23
BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol (2004) 2.21
Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr Relat Cancer (2008) 2.11
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
The new molecular markers DDIT3, STT3A, ARG2 and FAM129A are not useful in diagnosing thyroid follicular tumors. Mod Pathol (2011) 2.08
Young adult bone marrow-derived endothelial precursor cells restore aging-impaired cardiac angiogenic function. Circ Res (2002) 2.03
Definitions of bullying: a comparison of terms used, and age and gender differences, in a fourteen-country international comparison. Child Dev (2002) 2.00
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett (2004) 2.00
Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest (2011) 1.97
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab (2008) 1.95
The diversity present in 5140 human mitochondrial genomes. Am J Hum Genet (2009) 1.90
Bone marrow cells in the 'pre-metastatic niche': within bone and beyond. Cancer Metastasis Rev (2006) 1.89
IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell (2003) 1.86
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice. Proc Natl Acad Sci U S A (2011) 1.82
The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci U S A (2003) 1.80
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab (2013) 1.76
Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med (2007) 1.72
Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res (2005) 1.71
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab (2014) 1.71
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns. Mod Pathol (2010) 1.70
Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A (2009) 1.67
The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res (2007) 1.65
Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res (2006) 1.62
Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch (2005) 1.62
Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol (2002) 1.61